These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21551021)

  • 1. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
    Goto S; Komaba H; Moriwaki K; Fujimori A; Shibuya K; Nishioka M; Kim JI; Yoshiya K; Shin J; Hasegawa H; Taniguchi M; Fujii H; Nishi S; Kamae I; Fukagawa M
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1375-84. PubMed ID: 21551021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
    Park H; Rascati KL; Keith MS; Hodgkins P; Smyth M; Goldsmith D; Akehurst R
    Value Health; 2011 Dec; 14(8):1002-9. PubMed ID: 22152168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis.
    Vegter S; Tolley K; Keith MS; Postma MJ
    Value Health; 2011; 14(6):852-8. PubMed ID: 21914505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
    Keith MS; Wilson RJ; Preston P; Copley JB
    Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease.
    Brennan A; Akehurst R; Davis S; Sakai H; Abbott V
    Value Health; 2007; 10(1):32-41. PubMed ID: 17261114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: A systematic review.
    Rizk R; Hiligsmann M; Karavetian M; Evers SM
    Nephrology (Carlton); 2016 Mar; 21(3):178-87. PubMed ID: 26246269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
    Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
    Keith MS; Sibbel S; Copley JB; Wilson RJ; Brunelli SM
    Clin Ther; 2014 Oct; 36(10):1431-42.e1. PubMed ID: 25150194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients.
    Nguyen HV; Bose S; Finkelstein E
    BMC Nephrol; 2016 Apr; 17(1):45. PubMed ID: 27121505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
    St Peter WL; Wazny LD; Weinhandl ED
    Am J Kidney Dis; 2018 Feb; 71(2):246-253. PubMed ID: 29195858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
    Ogata H; Fukagawa M; Hirakata H; Kagimura T; Fukushima M; Akizawa T;
    JAMA; 2021 May; 325(19):1946-1954. PubMed ID: 34003226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
    Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
    J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.
    Ruggeri M; Bellasi A; Cipriani F; Molony D; Bell C; Russo D; Di Iorio B
    J Nephrol; 2015 Oct; 28(5):593-602. PubMed ID: 25027030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and baseline characteristics of the LANDMARK study.
    Ogata H; Fukagawa M; Hirakata H; Kaneda H; Kagimura T; Akizawa T;
    Clin Exp Nephrol; 2017 Jun; 21(3):531-537. PubMed ID: 27405619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.